

OTC Markets Group

Joining us today is Mark Edwards the President and CEO of Kane Biotech the trades on our OTCQB Venture Market under the ticker KNBLF. Kane Biotech is a Canadian-based biotechnology company engaged in the discovery development and commercialization of products that prevent and remove microbial biofilms. Mark, thanks so much for joining us today.

Marc Edwards

Thanks for having me.

OTC Markets Group

So Mark, you joined us back in 2020 to discuss Kane Biotech's story and we're very pleased to have you back for an update. To start, remind us why biofilms are a health threat to humans and animals, and the types of solutions and applications you develop.

Marc Edwards

Well, Biofilms are a glue-like substance that bacteria and Fungus secrete which makes them very hard to remove physically but also makes them highly resistant to antibiotics and antibacterial and are a known major contributor to antibiotic resistance. Currently, we operate in in 3 Markets, so, we first started animal health where we have a full line of pet oral care products because plaque and tartar on your teeth and as well as your pet's teeth are biofilms. And unfortunately our dogs and cats don't have some so brushing their teeth is their own teeth is complicated so we have a water outive you put in your dog's drinking water and it basically turns it into Mouse wash. We work in Dermatology. We have a line of shampoos and scalp care products again. Biofilms are in many cases, an important contributor to issues such as dandruff and irritation brought on by Subberadtic Dermatitis, we suspect they're contributed to acne, we suspect they're contributed to a topic Dermatitis, so on and so forth and then. Last and certainly not least as it's our main focus is an advanced wound care where biofilm impaired healing is really the biggest unresolved problems in wound care and what that means is that people who have these chronic wounds are. Are getting amputated or they're actually leading to death in some cases. So It's an important problem and we think we've got some really good solutions.

OTC Markets Group

So excellent. So as a leader in biofilm research give us an update on Kane Biotech's patents, trials, and technologies.

Marc Edwards

So very opportune time for us to be talking Cecilia, 3 big announcements in the last couple of weeks the first one and for me was really one of the biggest was, in in late March we announced that we had successfully completed our safety and biocompatibility study for our dispersant b wound gel in preparation for the human clinical trials both the safety and biocompatibility as well as the tests as well as the upcoming trials are funded by the U.S. army through MTech which goes to show you how big a problem biofilm impaired healing is and what makes this these trials particularly compelling is that are in vivo tests so that both. Infected and uninfected wounds showed significantly accelerated wound healing and then 2 other big announcements this week this week we announced that we had appointed Dr Greg Schultz as our chief scientific officer Greg is Professor Emervis at the University Of Florida and is I'll say a world renowned biofilm expert. But maybe the world renowned biofilm experts to give an example and I'm currently in phoenix at the symposium on advanced wound care and Greg is giving 5 talks to close to 2000 professionals that are here. So it's a big coup for Kane to be bringing on Greg as our chief science officer. He's really going to help us. move our 2 wound care programs forward and. Help us bring in some key partners there to grow this business and then just see yesterday. We announced that we had received the veterinary oral health council seal of approval of acceptance for petwater. This is following 2 clinical trials that show that our pet water out of significantly reduces the accumulation of tartar under your dog's teeth, this triggers and this is important because it triggers milestone payments from our licensing partners. So we have licensing partners in the U.S. and for all of the Americas and we have a second partner. in in Europe Asia and Australia New Zealand and this will trigger like milestone payments as well as minimum royalty payments.

OTC Markets Group

So as the world enters a new phase of the pandemic which is now more like an endemic, tell us what you have learned over the last two years and how this affected your business.

Marc Edwards

So we're Canadian business and we did fairly well throughout the pandemic there were there were some good government programs which we took advantage of and we're really able to move our clinical programs forward. We created our first commercialization vehicle in in animal health where with a UK -based company and we put the whole deal together in 2020 and had never met these people face to face so that was unusual but certainly able to move forward, but what covid

really highlighted for me is that the work we're doing is really important as I mentioned earlier biofilms are a major contributor to antibiotic resistance which is another major global threat. Hopefully what we're doing can help prevent that.

OTC Markets Group

What types of projects and partnerships are in the pipeline for Kane Biotech in 2022?

Marc Edwards

So our 2 big projects are the 2 wound shells that that we're developing, the first one should and we're hoping to have FDA approval by the end of this year, that's based on our coactive plus technology and we're going to with our dispersant b program. We're going to be moving into clinical trials end of Q2 or in Q3, which will be an important milestone. Then in terms of partnerships we're making some very good progress toward securing strategic partnership in wound care and have multiple ongoing licensing discussions in in dermatology. So there continues to be a lot going on at Kane.

OTC Markets Group

Kane Biotech began trading on the OTCQB Venture Market in May of 2020 and is also traded on the TSX-V. How does cross trading on the OTCQB Market continue to increase your investor awareness in the U.S.?

Marc Edwards

Well it makes it a lot easier for U.S. investors to invest in Kane. The Canadian biotech markets is very small. Canadian biotech investors are few and far between multiples in the U.S. There's a lot more money in the U.S. There's a lot more interest in the sector in the U.S. and being listed on the OTCQB really allows us to make it easy for those investors to invest in Kane.

OTC Markets Group

Mark, it's been great talking with you. Thanks so much for the updates.

Marc Edwards

It's been great too, Cecilia. Thank you very much for having me and look forward to talking again soon.

OTC Markets Group

Absolutely. Kane Biotech trades under the symbol KNBLF on our OTCQB Venture Market.

**This is an autogenerated transcript and may contain typos.*